Sign inJoin waitlistJoin the waitlist

DP

Daniel Persky

Professor Emeritus · University of Arizona College of Medicine-Tucson

Credentials: · · · ·

History

University of Arizona College of Medicine-Tucson
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2003–2006
Internal Medicine
2000–2003
Albert Einstein College of Medicine
1996–2000
Harvard University
1992–1996

Research

Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study…
Journal of Clinical Oncology · 2008 · First of 10 authors · 217 citations
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas
Journal of Clinical Oncology · 2014 · 187 citations
Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review
Review · Blood Reviews · 2018 · 167 citations

Lisa Rimsza
15 papers
TM
Thomas Miller
15 papers
Jonathan Friedberg
13 papers
RF
Richard Fisher
13 papers
SP
Soham Puvvada
12 papers
AM
Ali McBride
10 papers
Daruka Mahadevan
10 papers
Sonali Smith
10 papers
Catherine Spier
9 papers
XR
Xavier Rivera
7 papers
AD
Alexey Danilov
6 papers
Faiz Anwer
6 papers

Grants

University of Arizona Cancer Center - Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $1.5M · University of Arizona

Clinical trials

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Principal investigator · Withdrawn · Phase 2
University of Arizona
2015–2017
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
Principal investigator · Completed · Phase 2
University of Arizona
2012–2017
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Principal investigator · Completed · Phase 2
SWOG Cancer Research Network
2011–2023
Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2010–2027